Barbara Rehermann

Barbara Rehermann

Auto-generated profile, based on publicly available information

Barbara Rehermann

Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
BRBarbara Rehermann
Barbara Rehermann
MNMichelina Nascimbeni
Michelina Nascimbeni

30 January 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
VRVito Racanelli
Vito Racanelli
BRBarbara Rehermann
Barbara Rehermann
The liver is a unique anatomical and immunological site in which antigen-rich blood from the gastrointestinal tract is pressed through a network of sinusoids and scanned by antigen-presenting cells and lymphocytes. The liver's lymphocyte population is selectively enriched in natural killer and natural killer T cells which play critical roles in first line immune defense against invading pathogens, modulation of liver injury and recruitment of circulating lymphocytes. Circulating lymphocytes come in close contact to antigens displayed by endothelial cells, Kupffer cells and liver resident dendritic cells in the sinusoids. Circulating lymphocytes can also contact hepatocytes directly, because the sinusoidal endothelium is fenestrated and lacks a basement membrane. This unique anatomy of the liver may facilitate direct or indirect priming of lymphocytes, modulate the immune response to hepatotrophic pathogens and contribute to some of the unique immunological properties of this organ, particularly its capacity to induce antigen-specific tolerance.

6 January 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LPLudmila Prokunina-Olsson
Ludmila Prokunina-Olsson
BMBrian Muchmore
Brian Muchmore
WTWei Tang
Wei Tang
RPRuth M Pfeiffer
Ruth M Pfeiffer
HPHeiyoung Park
Heiyoung Park
TOThomas R O'BRien
Thomas R O'BRien

1 November 2017 in Cell
Verified
Journal Article
Closed access
SRStephan P. Rosshart
Stephan P. Rosshart
BVBrian G. Vassallo
Brian G. Vassallo
DADavide Angeletti
Davide Angeletti
DHDiane S. Hutchinson
Diane S. Hutchinson
AMAndrew P. Morgan
Andrew P. Morgan
BRBarbara Rehermann
Barbara Rehermann

1 October 1996 in Nature Medicine
Verified
Journal Article
Closed access
BRBarbara Rehermann
Barbara Rehermann
CFCarlo Ferrari
Carlo Ferrari
CPClaudio Pasquinelli
Claudio Pasquinelli
FCFrancis Chisari
Francis Chisari

15 February 2000 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
TLT. Jake Liang
T. Jake Liang
BRBarbara Rehermann
Barbara Rehermann
LSLeonard B. Seeff
Leonard B. Seeff
JHJay H. Hoofnagle
Jay H. Hoofnagle
Approximately 4 million persons in the United States and probably more than 100 million persons worldwide are infected with hepatitis C virus. The virus has the unique ability to cause persistent infection in susceptible hosts after parenteral or percutaneous transmission, and its underlying mechanisms are not well understood. The immunologic correlates of protection and viral clearance and the pathogenesis of liver injury are yet to be defined, but recent studies suggest the importance of cell-mediated immune responses. Although 70% to 80% of infected persons become chronic carriers, most have relatively mild disease with slow progression. However, chronic and progressive hepatitis C carries significant morbidity and mortality and is a major cause of cirrhosis, end-stage liver disease, and liver cancer. Development of an effective hepatitis C virus vaccine is not imminent, but recent advances in technology and basic knowledge of molecular virology and immunology have engendered novel approaches to the fundamental problems encountered in vaccine development. Current therapy for hepatitis C, although effective in some patients, is problematic and still evolving. Advances in modern biology and immunology promise new therapies for this important disease.